and chronotropic responses to Iso, the !so-induced increase in CBF, presumably mediated by vascular 132-receptor stimula tion, was not affected by Glb. Intracoronary denopamine (0.1 J.Lg·kg-1 ·min-1 ), a 131-selective agonist, increased CBF, which was almost completely abolished by Glb. The increases in MVo2 induced by Iso or denopamine were similar before and after Glb, indicating that attenuation of the Iso-or denopamine induced increase in CBF by Glb did not result from the decrease in MVo2. These results indicate that Glb prevented the increase in CBF associated with increased MVo2 caused by 131-adrenoceptor stimulation. It is suggested that ATP sensitive K+ channels may play an important role in metabolic coronary vasodilation in dogs.
adenosine triphosphate-sensitive potassium channels; meta bolic coronary vasodilation; isoproterenol; denopamine; pinaci dil CORONARY CIRCULATION is unique in that blood flow is regulated largely by the myocardial metabolic state (7, 13, 35) . In normal conditions, metabolic vasodilation of coronary resistance artery takes place rapidly when a balance between myocardial oxygen demand and supply is jeopardized so that myocardial ischemia does not develop. Adenosine has been considered as a likely mediator of metabolic coronary vasodilation in that adenosine levels in the interstitial fluid and/ or coronary sinus blood increase when myocardial metabolism in creases by catecholamine infusion (2, 12, 14, 19, 30, 36) , rapid pacing (17) , sympathetic stimulation (17) , and aortic constriction (8) . However, it appears unlikely that adenosine plays an important role in mediating meta bolic coronary vasodilation, because adenosine A2-receptor blockers or adenosine deaminase did not affect metabolic coronary vasodilation (12, 20, 29, 31) .
Recently, several studies have suggested that ATP sensitive K+ channels may be involved importantly in control of coronary blood flow. It is shown that hypoxic coronary vasodilation and coronary reactive hyperemic response were significantly attenuated by glibenclamide (1, 6) , a specific blocker of ATP-sensitive K+ channels (9) . We have recently suggested that ATP-sensitive K+ channels are involved in regulation of coronary blood flow with no hypoxia or ischemia (11) . However, the role of the channels in metabolic coronary vasodilation asso ciated with increased myocardial oxygen consumption has not been determined. This study aimed to determine whether ATP-sensitive K+ channels contribute to the increase in coronary blood flow associated with aug mented myocardial metabolism caused by f31-adrenocep tor stimulation in anesthetized dogs.
METHODS

Experimental Preparation
Adult mongrel dogs (16-23 kg) of either sex were anesthe tized with an intravenous administration of pentobarbital sodium (25 mg/kg), intubated, and ventilated with a positive pressure respirator. Arterial pH, Po2, and Pco2 were main tained within the physiological range (pH = 7.30-7 .50, Po2 = 80-110 mmHg, Pco2 = 25-45 mmHg). Supplemental oxygen was given if needed. Left thoracotomy was performed in the fourth intercostal space and the pericardia! cradle was made.
An electromagnetic flow probe of an appropriate size was placed at the proximal segment of the left circumflex coronary artery (LCx) or at midportion of the left anterior descending coronary artery (LAD). For the measurement of regional myocardial function, a pair of miniature piezoelectric ultra sonic crystals (5 MHz, Murata, Kyoto) were placed in the subendocardial portion of myocardium in the region perfused by LCX as described previously (21) . A pneumatic cuff occluder was also placed distal to the flow probe for calibration of zero flow. A heparin-filled miniature needle was cannulated into the study artery just distal to the flow probe for drug infusion.
A polyethylene catheter was inserted into the aortic arch through the right carotid artery for the measurement of aortic pressure, and a 7-Fr catheter-tipped pressure transducer was inserted into the left ventricular (LV) cavity through the left carotid artery for the measurement of LV pressure (LVP).
Measurements
Aortic pressure (AoP) was measured using a strain-gauge transducer (Statham P23-Db, Statham Instruments). Acardia tachometer triggered by AoP pulse was utilized to monitor The end-systolic segment length was measured at 20 ms before peak negative LV dP/dt, and the end-diastolic segment length at the onset of rapid upstroke of positive LV dP /dt. Percent systolic segment shortening (%SS) was calculated as follows (end-diastolic length -end-systolic length) %SS = X 100 end-diastolic length Averaged o/cSS of five beats was used for analysis.
All variables were continuously monitored and recorded with use of a polygraph system (Polygraph 360, NEC San-Ei, Tokyo, Japan). The data were stored on tape using a digital audiotape recorder (PC-108M, Sony).
In sort:�e animals, to determine myocardial oxygen consump tion (MV02), oxygen saturation of arterial and coronary ve nous blood were measured (see Experimental Protocol). Oxy gen saturation of paired blood samples from the aortic arch and the coronary vein was measured by a calibrated oxygen analyzer (Unistat Oxymeter, American Optical, Buffalo, NY).
MV02 was calculated by the following formula MV02 (ml/min) = CBF (ml/min) x 0.0136
where Hb is hemoglobin, Sa0 2 is arterial blood oxygen satura tion, and Sv0 2 is coronary venous oxygen saturation.
Experimental Protocol
After completion of surgical preparations, dogs were allowed to stabilize for 30 min. Then, the following protocols were performed in five groups of animals. CBF was measured at a midportion of LAD. AoP, HR, LVP, and LV dP/dt were also monitored and recorded. Hemoglobin concentration was measured before and at the end of isoproter enol infusion in these dogs.
ProtocolS. In five dogs, denopamine (0.2-0.5 f.Lg· kg t. min 1)
was infused into the left main coronary artery before and during simultaneous infusion of glibenclamide (100 11-g/minl.
CBF at the midportion of LAD and MVo2 in myocardium perfused by LAD were determined as described in protocol 4.
CBF, Aop, HR, LVP, and LV dP /dt were also measured. 
Statistical Analysis
Data are shown as means ± SE. Paired data were compared using a paired Student's t test. Hemodynamic responses to isoproterenol before and during glibenclamide at three doses were compared using analysis of variance CANOVA) for re peated measures followed by Bonferroni's multiple-compari son tests. The effects of glibenclamide on the responses to pinacidil were also analyzed using ANOVA. Probability of < 0.05 was considered statistically significant. 
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10:] whereas AoP and HR did not change. Then HR in creased and AoP gradually decreased, presumably due to the systemic effects of isoproterenol. Thus, in this experiment, we analyzed the responses to isoproterenol at 30 s after the onset of infusion (the early response with no systemic effects) and at 2 min after the onset of infusion (the late response with the systemic effects). Because glibenclamide at graded doses inhibited the CBF response to isoproterenol similarly at the early and late phase, the responses to isoproterenol at the late phase were analyzed in the following experiments.
Ef f ects of Glibenclamide on Isoproterenol-Induced Coronary Vasodilation after the Treatment with
Bisoprolol (Protocol 2) Table 2 summarizes the effects of isoproterenol in fused into LCx (10 ng-kg-1-min-1) on hemodynamic variables before and during glibenclamide in the absence and presence of a [31-blocker bisoprolol (0.3 mglkg). Bisoprolol decreased baseline CBF at LCx, AoP, HR, peak-positive dP ldt, and %88 (P < 0.01). Bisoprolol attenuated the isoproterenol-induced increase in CBF (P < 0.01) and abolished the isoproterenol-induced change in AoP, HR, peak positive dP I dt, and %88. Mter the treatment with bisoprolol, glibenclamide did not affect baseline variables and did not alter the isoproter enol-induced increase in CBF.
Effects of Glibenclamide on Denopamine-Induced
Coronary Vasodilation (Protocol 3) CBF at LCx (P < 0.01), HR (P < 0.05), LV dPidt (P < 0.01), and %88 (P < 0.05) but did not alter AoP. Glibenclamide (30 1-Lg/min) did not alter baseline vari ables but markedly attenuated the denopamine-induced increase in CBF (P < 0.01) and %88 (P < 0.05).
Glibenclamide did not alter the denopamine-induced increase in HR or peak positive LV dPidt.
isoproterenol alone, which was not altered by glibencl amide (Fig. 2B) . The denopamine-induced increase in CBF was nearly abolished by glibenclamide (Fig. 2C) . by -30% (Fig. 2A) . The isoproterenol-induced increase in CBF after bisoprolol was � 70% of that induced by amide, but it did not alter coronary venous oxygen saturation and the arteriovenous oxygen difference after glibenclamide. Glibenclamide increased myocardial oxy gen extraction during isoproterenol infusion (P < 0.05).
Hemoglobin concentration did not change before and during isoproterenol infusion (12.9 ± 0.2 and 13.0 ± 0.2 g/dl, respectively).
Effects of Glibenclarnide on the Denopamine-Induced
Tne1·ease in MVo2 (Protocol 5) Table 5 summarizes the effects of denopamine infused into the left main coronary artery on CBF at LAD, LV dP/dt, AoP, HR, and oxygen saturation before and during glibenclamide. Glibenclamide attenuated the de nopamine-induced increase in CBF (P < 0.01) but did not significantly alter the increase in MVo2 evoked with denopamine. Glibenclamide tended to increase myocar dial oxygen extraction during denopamine infusion (P = 0.06). Figure 3 shows the effect of glibenclamide on the ratio of the increase in CBF to that in MVo2 evoked by isoproterenol (Fig. 3A) or denopamine (Fig. 3B) . The ratios during glibenclamide were significantly lower than those before glibenclamide (P < 0.05). Previous studies have demonstrated that ATP-sensi tive K+ channels exist in cardiomyocytes (25) (26) (27) as well as in vascular smooth muscle (5, 22, 24, 33) . The open probability of the channels increases when intracellular Table 5 . Effects of glibenclamide on denopamine-induced increase in CBF, Sa02, and Sv02, and hemodynamic variables Values are means± SE. ap < 0.05, b P < 0.01 vs. baseline. c P < 0.01, dp= 0.076, ep < 0.06 vs. control response to denopamine before glib enclamide.
ATP concentration falls. The opening of the channels in the vascular smooth muscle cell causes hyperpolariza tion of sarcolemmal membrane and subsequent vasore laxation (5, 24, 25) . It is also shown that glibenclamide is a selective blocker of ATP-sensitive K+ channels (6) and competitively antagonizes vasodilation evoked with ATP sensitive K +-channel openers such as pinacidil (28, 3 7) . Recently, Daut et al. (6) showed that, in isolated guinea pig hearts, hypoxic vasodilation of coronary vasculature was blocked by glibenclamide (6) . It has been demon strated that glibenclamide significantly attenuated reac tive hyperemia after brief coronary arterial occlusion ( 1) and ischemic vasodilation of coronary microvessels dis tal to a significant stenosis in the large coronary artery (15) . These results imply an important role of ATP sensitive K+ channels in coronary vasodilation resulting from the decrease in myocardial oxygen supply. More over, recent findings from our laboratory suggest that ATP-sensitive K+ channels may be involved in regula tion of CBF under physiological conditions without apparent hypoxia or ischemia, since glibenclamide at tenuated resting CBF in a dose-dependent manner in dogs (10) . However, the role of ATP-sensitive K+ chan nels in metabolic coronary vasodilation associated with the increase in MVo2 was not hitherto determined.
Isoproterenol-induced coronary vasodilation involves two mechanisms: direct stimulation of vascular r?>-recep tors and metabolic vasodilation secondary to the in crease in MVo2 (7, 35) . In this study, the treatment with a selective 13t-blocker bisoprolol (0.3 mg/kg) completely prevented the isoproterenol-induced increase in HR, peak positive dP I dt, and o/c:SS and reduced the increase in CBF evoked with isoproterenol by � 30% ( Table 3) .
We assume that the isoproterenol-induced increase in CBF after bisoprolol resulted from coronary vasodila tion mediated by direct stimulation of vascular 13z
receptors, since 131-receptor-mediated chronotropic and inotropic responses to isoproterenol were completely prevented by bisoprolol. This assumption is supported by a previous report that bisoprolol at the dose of 0.3 mg/kg primarily blocks cardiac 131-receptors but af f ects only modestly vascular 132-receptor in canine hearts (32) . It also has been shown that the predominant 13-receptor subtype in canine coronary resistance vessels is 132-receptor (7, 10, 18, 21, 35 Fig. 3 ). Thus glibenclamide did not affect coronary vasodilation mediated by direct stimulation of vascular 132-adrenoceptors. Furthermore, glibenclamide prevented the increase in CBF induced by denopamine, a selective 131-agonist. These results suggest that glibencl amide inhibited the increase in CBF caused by myocar dial r?>1-adrenoceptor stimulation.
The most important finding of this study is that glibenclamide attenuated the isoproterenol-or denopa mine-induced increase in CBF without altering the agonist-induced increases in estimated M Vo2 (Tables 4  and 5 2). The results of the experiments with bisoprolol sug gest that �1-receptor-mediated metabolic coronary vaso dilation accounted for -307r and vascular �rreceptor mediated coronary vasodilation accounted for -70o/c of the increase in CBF induced by isoproterenol in our experimental etting ( Table 2 ). The increa e in CBF evoked with denopamine was nearly aboli hed by glib enclamide (Fig. 2) . These results suggest that ATP- Table 1) . Inhibition of the denopa mine-induced increase in CBF by glibenclamide was associated with the smaller increase in o/c88 (Table 3) .
We consider that reduction in the denopamine-induced increase in %88 by glibenclamide was not the cause but (7), and thus the coronary vasculature was dilated in our preparation. Despite this limitation, �r agonists were able to augment MVo2 and to increase CBF, which suggests that metabolic regulation of coro nary vasculature was preserved.
The underlying mechanisms by which the increase in
MVo2 may cause opening of ATP-sensitive K channels are unknown and were not explored in this study.
Adenosine was previously postulated as a possible media tor of metabolic coronary vasodilation (2, 8, 14, 17, 19, 30, 36) . Recent studies have shown that coronary vasodi lation induced by adenosine was blocked by glibencl amide (1, 6). However, it is unlikely that adenosine was involved in this mechanism, since the treatment with adenosine receptor blockers or adenosine deaminase has little or a minor effect on metabolic control of coronary blood flow (11, 20, 31) .
It has been shown that a depletion of tissue oxygen tension is a stimulus to coronary vasodilation, suggest ing an important role of tissue oxygen tension in the local metabolic control of coronary blood flow (4, 7).
Recently, Nichols and Lederer (25) 
